Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).

The data showed that 100% of the ten patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.

To date, All ten patients enrolled in the study have been monitored for at least 3.5 years after treatment with Lomecel-BTM.

All patients are more than four years of age, with 2 being five years of age, and additional long-term follow-up is ongoing in the ELPIS I participants.

Historical results have shown that children with HLHS have approximately 20% mortality by five years.

In addition, about three years after the Stage 2 surgery, most of these patients undergo the third palliative surgery, the last of the standard sequence of surgeries that comprises the current standard of care for HLHS. To date, 5 of 5 of the eligible patients from the ELPIS I trial have already undergone this third surgery.

The company expects to present these updated data at a scientific conference later in 2023.

Price Action: LGVN shares are up 30.10% at $4.11 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.